BIOMAT Database Logo BIOMAT Database Logo

[High specificity in the molecular mechanism of the protective action of phosphocreatine on the myocardium in ischemia]. 1988

V A Saks, and L A Makhotina, and V L Lakomkin, and A Ia Shteĭnshneĭder, and V I Kapel'ko

To study the character of the mechanism of protective action of phosphocreatine on ischemic myocardium the effects of phosphocreatine (PCr) and phosphoarginine (PArg) were compared. PCr and PArg were shown to expose identical Ca2+-chelating properties and were used as their Na-salts. Only PCr protected the cardia function during ischemia and simultaneously inhibited the accumulation of lysophosphoglycerides, products of phospholipid degradation. PArg failed to exert both of these effects. By an EPR probe method PCr was shown to increase the order of structural organization of phospholipids in the cardiac sarcolemmal vesicles. The results show that the effect of PCr on ischemic myocardium is not due to nonspecific changes in the ion composition of a solution, but most probably due to highly specific effect of phosphocreatine on the phospholipid membrane of the cardiac cells sarcolemma.

UI MeSH Term Description Entries
D008246 Lysophospholipids Derivatives of PHOSPHATIDIC ACIDS that lack one of its fatty acyl chains due to its hydrolytic removal. Lysophosphatidic Acids,Lysophospholipid,Acids, Lysophosphatidic
D008297 Male Males
D009206 Myocardium The muscle tissue of the HEART. It is composed of striated, involuntary muscle cells (MYOCYTES, CARDIAC) connected to form the contractile pump to generate blood flow. Muscle, Cardiac,Muscle, Heart,Cardiac Muscle,Myocardia,Cardiac Muscles,Heart Muscle,Heart Muscles,Muscles, Cardiac,Muscles, Heart
D009943 Organophosphorus Compounds Organic compounds that contain phosphorus as an integral part of the molecule. Included under this heading is broad array of synthetic compounds that are used as PESTICIDES and DRUGS. Organophosphorus Compound,Organopyrophosphorus Compound,Organopyrophosphorus Compounds,Compound, Organophosphorus,Compound, Organopyrophosphorus,Compounds, Organophosphorus,Compounds, Organopyrophosphorus
D010725 Phosphocreatine An endogenous substance found mainly in skeletal muscle of vertebrates. It has been tried in the treatment of cardiac disorders and has been added to cardioplegic solutions. (Reynolds JEF(Ed): Martindale: The Extra Pharmacopoeia (electronic version). Micromedex, Inc, Englewood, CO, 1996) Creatine Phosphate,Neoton,Phosphocreatine, Disodium Salt,Phosphorylcreatine,Disodium Salt Phosphocreatine,Phosphate, Creatine
D010743 Phospholipids Lipids containing one or more phosphate groups, particularly those derived from either glycerol (phosphoglycerides see GLYCEROPHOSPHOLIPIDS) or sphingosine (SPHINGOLIPIDS). They are polar lipids that are of great importance for the structure and function of cell membranes and are the most abundant of membrane lipids, although not stored in large amounts in the system. Phosphatides,Phospholipid
D011919 Rats, Inbred Strains Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations or by parent x offspring matings carried out with certain restrictions. This also includes animals with a long history of closed colony breeding. August Rats,Inbred Rat Strains,Inbred Strain of Rat,Inbred Strain of Rats,Inbred Strains of Rats,Rat, Inbred Strain,August Rat,Inbred Rat Strain,Inbred Strain Rat,Inbred Strain Rats,Inbred Strains Rat,Inbred Strains Rats,Rat Inbred Strain,Rat Inbred Strains,Rat Strain, Inbred,Rat Strains, Inbred,Rat, August,Rat, Inbred Strains,Rats Inbred Strain,Rats Inbred Strains,Rats, August,Rats, Inbred Strain,Strain Rat, Inbred,Strain Rats, Inbred,Strain, Inbred Rat,Strains, Inbred Rat
D002415 Cats The domestic cat, Felis catus, of the carnivore family FELIDAE, comprising over 30 different breeds. The domestic cat is descended primarily from the wild cat of Africa and extreme southwestern Asia. Though probably present in towns in Palestine as long ago as 7000 years, actual domestication occurred in Egypt about 4000 years ago. (From Walker's Mammals of the World, 6th ed, p801) Felis catus,Felis domesticus,Domestic Cats,Felis domestica,Felis sylvestris catus,Cat,Cat, Domestic,Cats, Domestic,Domestic Cat
D003327 Coronary Disease An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels. Coronary Heart Disease,Coronary Diseases,Coronary Heart Diseases,Disease, Coronary,Disease, Coronary Heart,Diseases, Coronary,Diseases, Coronary Heart,Heart Disease, Coronary,Heart Diseases, Coronary
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug

Related Publications

V A Saks, and L A Makhotina, and V L Lakomkin, and A Ia Shteĭnshneĭder, and V I Kapel'ko
[Myocardium-protective effects of phosphocreatine in experimental ischemia-reperfusion].
February 1992, Cardiologia (Rome, Italy),
V A Saks, and L A Makhotina, and V L Lakomkin, and A Ia Shteĭnshneĭder, and V I Kapel'ko
[Possible mechanism of the protective effect of phosphocreatine on the ischemic myocardium].
April 1986, Biokhimiia (Moscow, Russia),
V A Saks, and L A Makhotina, and V L Lakomkin, and A Ia Shteĭnshneĭder, and V I Kapel'ko
[Protective effect of phosphocreatine on the myocardium (experimental study)].
January 1986, Vestnik Akademii meditsinskikh nauk SSSR,
V A Saks, and L A Makhotina, and V L Lakomkin, and A Ia Shteĭnshneĭder, and V I Kapel'ko
[Mechanism of the anti-arrhythmic action of phosphocreatine in acute myocardial ischemia].
April 1985, Kardiologiia,
V A Saks, and L A Makhotina, and V L Lakomkin, and A Ia Shteĭnshneĭder, and V I Kapel'ko
[The role of calcium ions in the molecular mechanism of the protective mechanism of exogenous phosphocreatine].
February 1992, Biokhimiia (Moscow, Russia),
V A Saks, and L A Makhotina, and V L Lakomkin, and A Ia Shteĭnshneĭder, and V I Kapel'ko
[Various aspects of protective effect of exogenous phosphocreatine on the ischemic myocardium].
January 1986, Vestnik Akademii meditsinskikh nauk SSSR,
V A Saks, and L A Makhotina, and V L Lakomkin, and A Ia Shteĭnshneĭder, and V I Kapel'ko
Protective action of methylprednisolone on the myocardium during experimental myocardial ischemia in the cat.
July 1974, Circulation research,
V A Saks, and L A Makhotina, and V L Lakomkin, and A Ia Shteĭnshneĭder, and V I Kapel'ko
[Effect of phosphocreatine on the lysophosphoglyceride levels in total ischemia of the rat myocardium].
April 1986, Biokhimiia (Moscow, Russia),
V A Saks, and L A Makhotina, and V L Lakomkin, and A Ia Shteĭnshneĭder, and V I Kapel'ko
The antiarrhythmic action of phosphocreatine in acute myocardial ischemia.
August 1985, Biochemical medicine,
V A Saks, and L A Makhotina, and V L Lakomkin, and A Ia Shteĭnshneĭder, and V I Kapel'ko
Participation of calcium ions in the molecular mechanism of cardioprotective action of exogenous phosphocreatine.
January 1991, Basic research in cardiology,
Copied contents to your clipboard!